The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption
Abstract
Acute kidney injury (AKI) is a common complication of critical illnesses and has a significant impact on outcomes, including mortality and morbidities. Unfortunately, apart from prophylactic measures, no effective treatment for this syndrome is known. Therefore, early recognition of AKI not only can provide better opportunities for preventive interventions, but also opens many gates for research and development of effective therapeutic options. Over the last few years, several new AKI biomarkers have been discovered and validated to improve early detection, differential diagnosis, and differentiation of patients into risk groups for progressive renal failure, need for renal replacement therapy (RRT), or death. These novel AKI biomarkers complement serum creatinine (SCr) and urine output, which are the standard diagnostic tools for AKI detection. In this article, we review the available literature on characteristics of promising AKI biomarkers that are currently the focus of preclinical and clinical investigations. These biomarkers include neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule 1 (KIM-1), liver-type fatty acid-binding protein, interleukin 18 (lL-18), insulin-like growth factor-binding protein 7, tissue inhibitor of metalloproteinase 2 (TIMP-2), calprotectin, urine angiotensinogen (AGT), and urine microRNA. We then describe the clinical performance of these biomarkers for diagnosis and prognostication. We also appraise each AKI biomarker’s advantages and limitations as a tool for early AKI recognition and prediction of clinical outcomes after AKI. Finally, we review the current and future states of implementation of biomarkers in the clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury
Mehta, R. L., Kellum, J. A., Shah, S. V., Molitoris, B. A., Ronco, C., Warnock, D. G., Levin, A., & the Acute Kidney Injury Network (2007) · Critical Care · doi:10.1186/cc5713 · Cited by 7,048
Self-citationBellomo, R., Ronco, C., Kellum, J. A., Mehta, R. L., Palevsky, P., & workgroup, T. A. (2004) · Critical Care · doi:10.1186/cc2872 · Cited by 6,781
Self-citationBellomo, R., Kellum, J. A., & Ronco, C. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61454-2 · Cited by 2,598
Self-citationMishra, J., Dent, C., Tarabishi, R., Mitsnefes, M. M., Ma, Q., Kelly, C., Ruff, S. M., Zahedi, K., Shao, M., Bean, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)74811-x · Cited by 2,394
Acute Kidney Injury and Chronic Kidney Disease as Interconnected Syndromes
Chawla, L. S., Eggers, P. W., Star, R. A., & Kimmel, P. L. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1214243 · Cited by 1,977
Kidney Injury Molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury
Han, W. K., Bailly, V., Abichandani, R., Thadhani, R., & Bonventre, J. V. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00433.x · Cited by 1,929
Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron
Flo, T. H., Smith, K. D., Sato, S., Rodriguez, D. J., Holmes, M. A., Strong, R. K., Akira, S., & Aderem, A. (2004) · Nature · doi:10.1038/nature03104 · Cited by 1,877
Mishra, J., Ma, Q., Prada, A., Mitsnefes, M., Zahedi, K., Yang, J., Barasch, J., & Devarajan, P. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000088027.54400.c6 · Cited by 1,749
Vogl, T., Tenbrock, K., Ludwig, S., Leukert, N., Ehrhardt, C., van Zoelen, M. A. D., Nacken, W., Foell, D., van der Poll, T., Sorg, C., et al. (2007) · Nature Medicine · doi:10.1038/nm1638 · Cited by 1,418 · cited 1×
“No singular receptor uses calprotectin signal transduction, but S100A8 and S100A9 have been noted to be endogenous activators of Toll-like receptor 4 [138].”
BackgroundDiscovery and validation of cell cycle arrest biomarkers in human acute kidney injury
Kashani, K., Al-Khafaji, A., Ardiles, T., Artigas, A., Bagshaw, S. M., Bell, M., Bihorac, A., Birkhahn, R., Cely, C. M., Chawla, L. S., et al. (2013) · Critical Care · doi:10.1186/cc12503 · Cited by 1,362
Self-citation
Cited by
Ostermann, M., Zarbock, A., Goldstein, S., Kashani, K., Macedo, E., Murugan, R., Bell, M., Forni, L., Guzzi, L., Joannidis, M., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.19209 · Cited by 677
Self-citationCritical appraisal and meta-analysis of biological variation estimates for kidney related analytes
Jonker, N., Aslan, B., Boned, B., Marqués-García, F., Ricós, C., Alvarez, V., Bartlett, W., Braga, F., Carobene, A., Coskun, A., et al. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-1168 · Cited by 26
de Oliveira Vilar Neto, J., da Silva, C. A., Meneses, G. C., Pinto, D. V., Brito, L. C., da Cruz Fonseca, S. G., de Sousa Alves, R., Martins, A. M. C., de Oliveira Assumpção, C., & De Francesco Daher, E. (2020) · Toxicology Research · doi:10.1093/toxres/tfaa028 · Cited by 11
Metadata
- Authors
- Kashani, K., Cheungpasitporn, W., & Ronco, C.
- Venue
- Clinical Chemistry and Laboratory Medicine (CCLM)
- Publisher
- Walter de Gruyter GmbH
- Published
- 2017-07-26
- Volume
- 55
- Issue
- 8
- Pages
- 1074-1089
- ISSN
- 1434-6621 (ISSN-L)
- 1437-4331
- OpenAlex
- W2572405581
- Cited by
- 289
- References
- 163
- FWCI
- 26.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption. https://app.cochat.ai/papers/10.1515/cclm-2016-0973
- The paper
- Kashani, K., Cheungpasitporn, W., & Ronco, C. (2017). Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption. Clinical Chemistry and Laboratory Medicine (CCLM). https://doi.org/10.1515/cclm-2016-0973
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.